Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 2/20 | 0.40 |
| ▸ | CALCRL | Q16602 | 19/20 | 0.39 |
| ▸ | RAMP1 | O60894 | 1/20 | 0.39 |
| ▸ | MRGPRX2 | Q96LB1 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15935909 | 0.92 | CALCRL (0.39) | KCNH2CALCRLRAMP1MRGPRX2 | |
| SCHEMBL13062686 | 0.88 | CALCRL (0.49) | KCNH2CALCRLRAMP1MRGPRX2 | |
| SCHEMBL439306 | 0.83 | CALCRL (0.54) | KCNH2CALCRL | |
| SCHEMBL14146300 | 0.83 | CALCRL (0.54) | KCNH2CALCRL | |
| SCHEMBL15701569 | 0.83 | CALCRL (0.54) | KCNH2CALCRL | |
| SCHEMBL13748824 | 0.80 | CALCRL (0.48) | KCNH2CALCRLRAMP1MRGPRX2 | |
| SCHEMBL13062691 | 0.79 | CALCRL (0.40) | CALCRL | |
| SCHEMBL13062475 | 0.79 | CALCRL (0.39) | KCNH2CALCRLRAMP1MRGPRX2 | |
| SCHEMBL15701573 | 0.76 | CALCRL (0.64) | CALCRL | |
| SCHEMBL14146293 | 0.75 | CALCRL (0.56) | KCNH2CALCRLRAMP1MRGPRX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100324023-A1 | IMIDAZOBENZAZEPINE CGRP RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME CORP. (US) | 2010-12-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100324023-A1 | IMIDAZOBENZAZEPINE CGRP RECEPTOR ANTAGONISTS | BDKRB1, CCKBR, CALCRL | KCNH2 72/4885CALCRL 3/4885RAMP1 53/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.